ArticleCancer medicine2021
Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review.BJU international · 2025Pooled it
- Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Real-World Treatment Patterns in Patients with Metastatic Castration-Sensitive Prostate Cancer in Japan: A Retrospective Health Administrative Data Analysis.Advances in therapy · 2026Article
- Treatment options in hormone-sensitive prostate cancer: targeting the androgen-sensitive pathway.Future oncology (London, England) · 2025Review
- Article
- Treatment Landscape for Older Men With Metastatic Hormone-Sensitive Prostate Cancer in the United States.Cancer medicine · 2025Article
- Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States From 2017 to 2023.JCO oncology practice · 2025Article
- Current landscape in first-line treatment of metastatic hormone sensitive prostate cancer: a cost-effectiveness focused review.The oncologist · 2025Review
- Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada.Future oncology (London, England) · 2025Article
- Efficacy and safety of darolutamideFrontiers in pharmacology · 2025Article
- Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate Cancer.JAMA network open · 2024Article
- Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.Prostate cancer and prostatic diseases · 2024Article
- Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy.International journal of urology : official journal of the Japanese Urological Association · 2024Article
- Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database.Urologic oncology · 2024Article
- Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry.Prostate cancer and prostatic diseases · 2024Article
- Prostate cancer cell-derived exosomes ZNF667-AS1 reduces TGFBR1 mRNA stability to inhibit Treg expansion and DTX resistance by binding to U2AF1.Molecular medicine (Cambridge, Mass.) · 2024Article
- Lost opportunities: the underutilization of castrate-resistant prostate cancer treatment in real-world settings.Translational andrology and urology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited real-world data exist on treatment patterns and outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC).
methodsA retrospective cohort study was conducted, using the Veterans Health Administration claims database (April 2013-March 2018). Among 369,734 prostate cancer patients, we selected all men who developed metastases within 90 days before or after medical/surgical castration and who received androgen deprivation therapy (ADT). Patients were categorized into four cohorts: ADT-only (± <90-day nonsteroidal anti-androgen [NSAA] use), ADT + NSAA, ADT + docetaxel, and ADT + abiraterone. Main outcomes were treatment patterns, time-to-progression to metastatic castration-resistant disease, and overall survival. Multivariable analysis and sensitivity analysis were conducted.
resultsOf 1395 patients, 874 (63%) received ADT-only, 338 (24%) received ADT + NSAA, 108 (8%) received ADT + docetaxel, and 75 (5%) received ADT + abiraterone. Proportions on ADT-only and ADT + NSAA declined (from 66% to 60% and from 31% to 17%, respectively) over the study period, while proportions prescribed ADT + docetaxel or abiraterone increased from 3% to 9% and from 1% to 15%, respectively. Patients treated with ADT + NSAA had similar risks of castration-resistant disease (hazard ratio [HR] 1.05; 95% confidence interval [CI]: 0.87, 1.26) and overall mortality (HR 1.22; 95% CI: 0.97, 1.54) as ADT-only.
conclusionsMost patients with mCSPC initiating ADT received ADT-only or ADT + NSAA, despite the emergence of docetaxel and novel hormonal therapies. Even in the most recent period (2017 to early 2018), only 24% of men received intensified therapy with agents known to prolong survival versus ADT-only. These data in real-world clinical practice suggest substantial room for improved outcomes in patients with mCSPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.